Warfarin prophylaxis in patients with non-valvular atrial fibrillation
may be one of the most valuable public-health interventions. Barriers
to its optimal utilization include wariness about bleeding complicati
ons and concern about age-related sensitivity to the drug. The risks,
however, may be minimized by creation of anticoagulation clinics to en
sure optimal dosing and follow-up.